BMJ Best Practice

参考文献

关键文献

Spinks AB, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011;(6):CD002851.

参考文章

1.  Stern RM, Koch KL, Andrews P. Nausea of motion sickness. In: Stern RM, Koch KL, Andrews P. Nausea: mechanisms and management. New York, NY: Oxford Press; 2011:331-353.

2.  Benson AJ, Stott JR. Motion sickness. In: Rainford DJ, Gradwell DP. Ernsting's aviation medicine. 4th ed. London, UK: Hodder Arnold, Hodder Education; 2006:459-475.

3.  Hu S, Grant WF, Stern RM, et al. Motion sickness severity and physiological correlates during repeated exposures to a rotating optokinetic drum. Aviat Space Environ Med. 1991;62:308-314.

4.  Guerraz M, Yardley L, Bertholon P, et al. Visual vertigo: symptom assessment, spatial orientation and postural control. Brain. 2001;124:1646-1656.

5.  Stanney KM, Hale KS, Nahmens I, et al. What to expect from immersive virtual environment exposure: influences of gender, body mass index, and past experience. Hum Factors. 2003;45:504-520.

6.  Kennedy RS, Fowlkes JE. Simulator sickness is polygenic and polysymptomatic: implications for research. Int J Aviat Psychol. 1992;2:23-38.

7.  Kennedy R, Lane N, Lilienthal M, et al. Profile analysis of simulator sickness symptoms: application to virtual reality environments. Presence. 1992;1:295-301.

8.  Golding JF, Stott JR. Effect of sickness severity on habituation to repeated motion challenges in aircrew referred for airsickness treatment. Aviat Space Environ Med. 1995;66:625-630.

9.  Turner M, Griffin MJ. Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics. 1999;42:444-461.

10.  Flanagan MB, May JG, Dobie TG. Sex differences in tolerance to visually-induced motion sickness. Aviat Space Environ Med. 2005;76:642-646.

11.  Kennedy RS, Lanham DS, Massey CJ, et al. Gender differences in simulator sickness incidence: implications for military virtual reality systems. Safe J. 1995;25:69-76.

12.  Klosterhalfen S, Kellermann S, Pan F, et al. Effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med. 2005;76:1051-1057.

13.  Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med. 1988;59:399-406.

14.  Stern RM, Hu S, LeBlanc R, et al. Chinese hyper-susceptibility to vection-induced motion sickness. Aviat Space Environ Med. 1993;64: 827-830.

15.  Golding JF, Mueller AG, Gresty MA. A motion sickness maximum around the 0.2 Hz frequency range of horizontal translational oscillation. Aviat Space Environ Med. 2001;72:188-192.

16.  Lawther A, Griffin MJ. Prediction of the incidence of motion sickness from the magnitude, frequency, and duration of vertical oscillation. J Acoust Soc Am. 1987;82:957-966.

17.  O'Hanlon JF, McCauley ME. Motion sickness incidence as a function of the frequency and acceleration of vertical sinusoidal motion. Aerosp Med. 1974;45:366-369.

18.  Kennedy RS, Drexler J, Kennedy RC. Research in visually induced motion sickness. Appl Ergon. 2010;41:494-503.

19.  Bijveld MM, Bronstein AM, Golding JF, et al. Nauseogenicity of off-vertical axis rotation vs. equivalent visual motion. Aviat Space Environ Med. 2008;79:661-665.

20.  Drummond PD. Triggers of motion sickness in migraine sufferers. Headache. 2005;45:653-656.

21.  Stern RM, Koch KL, Stewart WR, et al. Spectral analysis of tachygastria recorded during motion sickness. Gastroenterol. 1987;92:92-97.

22.  Neimer J, Eskiizmirliler S, Ventre-Dominey J, et al. Trains with a view to sickness. Curr Biol. 2001;11:R549-R550.

23.  Williamson MJ, Thomas MJ, Stern RM. The contribution of expectations to motion sickness symptoms and gastric activity. Psychosom Res. 2004;56:721-726.

24.  Houchens PW, Jones MB. Behavioral contagion in an experimental motion environment. Aviat Space Environ Med. 2003;74:649-653.

25.  Zajonc TP, Roland PS. Vertigo and motion sickness. Part II: Pharmacologic treatment. Ear Nose Throat J. 2006;85:25-35.

26.  Zajonc TP, Roland PS. Vertigo and motion sickness. Part I: vestibular anatomy and physiology. Ear Nose Throat J. 2005;84:581-584.

27.  Ventre-Dominey J, Luyat M, Denise P, et al. Motion sickness induced by otolith stimulation is correlated with otolith-induced eye movements. Neuroscience. 2008;155:771-779.

28.  Dai M, Kunin M, Raphan T, et al. The relation of motion sickness to the spatial-temporal properties of velocity storage. Exp Brain Res. 2003;151:173-189.

29.  Cohen B, Dai M, Yakushin SB, et al. Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res. 2008;171:543-553.

30.  Stern RM, Leibowitz HW, Unblad I, et al. Tachygastria and motion sickness. Aviat Space Environ Med. 1985;56:1074-1077.

31.  Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology. 2005;65:620-622.

32.  von Reinhart J. Histamin-intoleranz: histamin und seekrankheit. Stuttgart: Thieme; 2004.

33.  Lichtenberg BK, Young LR, Arrott AP. Human ocular counterrolling induced by varying linear accelerations. Exp Brain Res. 1982;48:127-136.

34.  Merfeld DM, Park S, Gianna-Poulin C, et al. Vestibular perception and action employ qualitatively different mechanisms. II. VOR and perceptual responses during combined Tilt&Translation. J Neurophysiol. 2005;94:199-205.

35.  Merfeld DM, Park S, Gianna-Poulin C, et al. Vestibular perception and action employ qualitatively different mechanisms. I. Frequency response of VOR and perceptual responses during Translation and Tilt. J Neurophysiol. 2005;94:186-198.

36.  Wood SJ. Human otolith-ocular reflexes during off-vertical axis rotation: effect of frequency on tilt-translation ambiguity and motion sickness. Neurosci Lett. 2002;323:41-44.

37.  Money KE, Cheung BS. Another function of the inner ear: facilitation of the emetic response to poisons. Aviat Space Environ Med. 1983;54:208-211.

38.  Treisman M. Motion sickness: an evolutionary hypothesis. Science. 1977;197:493-495.

39.  Yates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull. 1998;47:395-406.

40.  Yen Pik Sang F, Billar JP, Gresty MA, et al. Effect of a novel motion desensitization training regime and controlled breathing on habituation to motion sickness. Percept Mot Skills. 2005;101:244-256.

41.  Drummond PD, Granston A. Facial pain increases nausea and headache during motion sickness in migraineurs. Brain. 2004;127:526-534.

42.  Pavlou M, Lingeswaran A, Davies RA, et al. Simulator based rehabilitation in refractory dizziness. J Neurol. 2004;251:983-995.

43.  Golding JF, Prosyanikova O, Flynn M, et al. The effects of smoking nicotine tobacco versus smoking deprivation on motion sickness. Aviat Space Environ Med. 2008;79:262.

44.  Redfern MS, Furman JM, Jacob RG. Visually induced postural sway in anxiety disorders. J Anxiety Disord. 2007;21:704-716.

45.  Redfern MS, Yardley L, Bronstein AM. Visual influences on balance. J Anxiety Disord. 2001;15:81-94.

46.  Romas RT, Jacob RG, Lilienfeld SO. Space and motion discomfort in Brazilian versus American patients with anxiety disorders. J Anxiety Disord. 1997;11:131-139.

47.  Golding JF, Kadzere P, Gresty MA. Motion sickness susceptibility fluctuates through the menstrual cycle. Aviat Space Environ Med. 2005:76; 970-973.

48.  Stern RM, Hu S, Anderson RB, et al. The effects of fixation and restricted visual field on vection-induced motion sickness. Aviat Space Environ Med. 1990;61:712-715.

49.  Denise P, Vouriot A, Normand H, et al. Effect of temporal relationship between respiration and body motion on motion sickness. Auton Neurosci. 2009;151:142-146.

50.  Golding JF. Predicting individual differences in motion sickness susceptibility by questionnaire. Pers Individ Dif. 2006;41:237-248.

51.  Jokerst MD, Gatto M, Fazio R, et al. Slow deep breathing prevents the development of tachygastria and symptoms of motion sickness. Aviat Space Environ Med. 1999;70:1189-1192.

52.  Yen Pik Sang FD, Billar JP, Golding JF, et al. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape. J Travel Med. 2003;10:108-111.

53.  Yen Pik Sang FD, Golding JF, Gresty MA. Suppression of sickness by controlled breathing during mildly nauseogenic motion. Aviat Space Environ Med. 2003;74:998-1002.

54.  Wood CD, Graybiel A. Evaluation of 16 antimotion sickness drugs under controlled laboratory conditions. Aerospace Med. 1968;39:1341-1344.

55.  Spinks AB, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011;(6):CD002851.

56.  Burton MJ, Roland PS, Rosenfeld RM. Extracts from The Cochrane Library: Scopolamine (hyoscine) for preventing and treating motion sickness. Otolaryngol Head Neck Surg. 2010;142:468-471.

57.  Stewart JJ, Wood MJ, Parish RC, et al. Prokinetic effects of erythromycin after antimotion sickness drugs. J Clin Pharmacol. 2000;40:347-353.

58.  Bar R, Gil A, Tal D. Safety of double-dose transdermal scopolamine. Pharmacotherapy. 2009;29:1082-1088.

59.  Howland J, Rohsenow DJ, Minsky S, et al. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time. Int J Occup Environ Health. 2008;14:250-256.

60.  Nachum Z, Shahal B, Shupak A, et al. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther. 2001;296:121-123.

61.  Cowings PS, Toscano WB. Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms. J Clin Pharmacol. 2000;40:1154-1165.

62.  Golding JF, Stott JR. Objective and subjective time courses of recovery from motion sickness assessed by repeated motion challenges. J Vestib Res. 1997;7:421-428.

63.  Ressiot E, Dolz M, Bonne L, et al. Prospective study on the efficacy of optokinetic training in the treatment of seasickness. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130:263-268.

64.  Stroud KJ, Harm DL, Klaus DM. Preflight virtual reality training as a countermeasure for space motion sickness and disorientation. Aviat Space Environ Med. 2005;76:352-356.

65.  Dobie TG, May JG. Cognitive-behavioural management of motion sickness. Aviat Space Environ Med. 1994;65:C1-C2.

66.  Toscano WB, Cowings PS. Reducing motion sickness: a comparison of autogenic-feedback training and an alternative cognitive task. Aviat Space Environ Med. 1982;53:449-453.

67.  Javid FA, Naylor RJ. The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav. 2002;73:979-989.

68.  Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit. 2006;12:PI1-PI7.

69.  Gupta Y, Chaudhary G. Effect of antiemetic drugs on decrease in gastric emptying in experimental model of motion sickness in rats. Acta Pharmacol Sin. 2003;24:296-300.

70.  Valoti M, Frosini M, Dragoni S, et al. Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. Methods Find Exp Clin Pharmacol. 2003;25:377-381.

71.  Klocker N, Hanschke W, Toussaint S, et al. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci. 2001;13:227-232.

72.  Ahmed S, Sileno AP, de Meireles JC, et al. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res. 2000;17:974-977.

73.  Simmons RG, Phillips JB, Lojewski RA, et al. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med. 2010;81:405-412.

74.  Streitberger K, Ezzo J, Schneider A. Acupuncture for nausea and vomiting: an update of clinical and experimental studies. Auton Neurosci. 2006;129:107-117.

75.  Hu S, Stern RM, Koch KL. Electrical acustimulation relieves vection-induced motion sickness. Gastroenterology. 1992;102:1854-1858.

76.  Grunfeld E, Price C, Goadsby P, et al. Migraine, motion sickness and menstruation in mariners. Lancet. 1998;351:1106.

使用此内容应接受我们的免责声明